Mechanism of Action

Acts via oxytocin receptors. Stimulates uterine smooth muscle contraction, milk ejection. Central effects on social bonding, trust, stress response, and appetite regulation via hypothalamic circuits.

Clinical Use

FDA-approved for obstetric indications (labor induction, postpartum hemorrhage). Non-obstetric use: investigational only.

Contraindications

Antepartum use without clear obstetric indication. Water intoxication risk at high doses. Cervical ripening agents interaction.

Evidence Summary

Extensive clinical use for obstetric indications. Non-obstetric trials largely negative or inconclusive. ASD trial definitive negative (NEJM 2021).

Key Studies
  • 1.Sikich et al., NEJM 2021 (ASD Phase II) — NO significant benefit over placebo on primary or secondary outcomes. Largest, most rigorous oxytocin/ASD trial. NEGATIVE RESULT. n=290
  • 2.Wronski et al., Contemp Clin Trials 2022 (MGH Obesity RCT) — intranasal oxytocin 4x daily in BMI 30+ adults. Primary: weight loss. NIH-funded. Results pending
Evidence Gaps

No Phase III trial completed for any non-obstetric indication. ASD failure (NEJM 2021, n=290) was definitive. Intranasal formulations not FDA-approved.

Emerging Research

MGH obesity Phase II RCT (intranasal in BMI 30+, NIH-funded, fMRI endpoints). Results pending.

iRemedy Sourcing Status
AVAILABLE
Available — FDA-listed (obstetric). Compounding API available

iRemedy is a 50-state licensed, NABP-accredited wholesale distributor. Peptides supplied with full CoA, DSCSA serialization, and UPS Healthcare cold chain logistics. Wholesale to licensed healthcare facilities and compounding pharmacies only.

← Back to Peptide Library ← Previous: Orforglipron Next: Pegvisomant →
Request Peptide Catalog →